Poseida Q1 rev $28.1M, net loss $24.3M; Astellas $50M upfront collab, new CMO

Poseida Therapeutics, Inc.

2024-Q1 EPS reported -$0.25 revenue$28,142,000

Revenue $28.1M vs $10.3M YoY; net loss $24.3M vs $38.8M; cash $198.6M, runway into H2 2025.
Astellas research collaboration: $50M upfront, up to $550M milestones, low double-digit royalties for solid tumor CAR-T.
Roche partnership: $30M milestone in Q1, $15M expected May 2024; total $95M in 2024 milestones/upfront.
P-BCMA-ALLO1 data: 60% overall response rate in RRMM patients after prior BCMA-directed therapy.
Appointed Syed Rizvi, M.D., as Chief Medical Officer in April 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Poseida Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Poseida Therapeutics, Inc. (the “Company”) issued a press release announcing its updates and financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-059522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.